FI920217A7 - Angiotensiini II reseptoria salpaavia 2,3,6-substituoituja kinatsolinoneja - Google Patents

Angiotensiini II reseptoria salpaavia 2,3,6-substituoituja kinatsolinoneja Download PDF

Info

Publication number
FI920217A7
FI920217A7 FI920217A FI920217A FI920217A7 FI 920217 A7 FI920217 A7 FI 920217A7 FI 920217 A FI920217 A FI 920217A FI 920217 A FI920217 A FI 920217A FI 920217 A7 FI920217 A7 FI 920217A7
Authority
FI
Finland
Prior art keywords
angiotensin
receptor antagonists
substituted quinazolinones
quinazolinones
substituted
Prior art date
Application number
FI920217A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI920217L (fi
FI920217A0 (fi
Inventor
Jeremy Ian Levin
Aranapakam M Venkatesan
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI920217A0 publication Critical patent/FI920217A0/fi
Publication of FI920217L publication Critical patent/FI920217L/fi
Publication of FI920217A7 publication Critical patent/FI920217A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Fats And Perfumes (AREA)
FI920217A 1991-01-30 1992-01-17 Angiotensiini II reseptoria salpaavia 2,3,6-substituoituja kinatsolinoneja FI920217A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64849291A 1991-01-30 1991-01-30

Publications (3)

Publication Number Publication Date
FI920217A0 FI920217A0 (fi) 1992-01-17
FI920217L FI920217L (fi) 1992-07-31
FI920217A7 true FI920217A7 (fi) 1992-07-31

Family

ID=24601009

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920217A FI920217A7 (fi) 1991-01-30 1992-01-17 Angiotensiini II reseptoria salpaavia 2,3,6-substituoituja kinatsolinoneja

Country Status (23)

Country Link
US (2) US5290780A (enExample)
EP (1) EP0497150B1 (enExample)
JP (1) JP2758766B2 (enExample)
KR (1) KR920014805A (enExample)
CN (1) CN1037440C (enExample)
AT (1) ATE164158T1 (enExample)
AU (2) AU642573B2 (enExample)
CA (1) CA2060154A1 (enExample)
CZ (1) CZ281429B6 (enExample)
DE (1) DE69224763T2 (enExample)
DK (1) DK0497150T3 (enExample)
ES (1) ES2117014T3 (enExample)
FI (1) FI920217A7 (enExample)
GR (1) GR3026592T3 (enExample)
HU (1) HUT61748A (enExample)
IE (1) IE920142A1 (enExample)
IL (1) IL100711A0 (enExample)
NO (1) NO920298L (enExample)
NZ (1) NZ241343A (enExample)
PL (1) PL293316A1 (enExample)
SK (1) SK279004B6 (enExample)
TW (1) TW282467B (enExample)
ZA (1) ZA92392B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
DK0618207T3 (da) * 1993-03-24 1999-08-30 American Home Prod Substituerede pyridopyrimidiner som antihypertensiva
US5358951A (en) * 1993-04-23 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
US5610301A (en) * 1993-07-01 1997-03-11 American Cyanamid Company Process for the regioselective n-alkylation of quinazolinones
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US5338736A (en) * 1993-10-07 1994-08-16 American Cyanamid Company Angiotensin II receptor blocking 2,3,6-substituted quinazolinones
ATE176784T1 (de) * 1994-09-20 1999-03-15 Wakunaga Seiyaku Kk Verfahren zur herstellung von n- biphenylmethylthiadiazolin derivaten oder deren salzen sowie dafür benötigte zwischen verbindungen
US5760220A (en) * 1995-06-07 1998-06-02 American Home Products Corporation Process for preparation of biphenyl derivatives
EP0846117B1 (en) * 1995-06-07 2003-05-14 Wyeth Process for preparation of biphenyl derivatives
US5739330A (en) * 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
US5763608A (en) * 1996-02-05 1998-06-09 Hoechst Celanese Corporation Process for preparing pyrimidine derivatives
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
US20060047952A1 (en) * 2002-10-18 2006-03-02 Koninklijke Philips Electronics, N.V. Method, system, device , signal and computer program product for metadata protection in tv-anytime
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
CN107056715B (zh) * 2017-04-07 2019-07-30 江南大学 一种增强TRPV4-KCa2.3复合体耦联度的化合物及其在抗高血压中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
CS272018B1 (en) * 1988-11-01 1990-12-13 Fisnerova Ludmila Ethereal derivatives of 4/3h/-quinazolinone
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5240928A (en) * 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones

Also Published As

Publication number Publication date
CS25592A3 (en) 1992-08-12
JPH0578332A (ja) 1993-03-30
FI920217L (fi) 1992-07-31
US5405849A (en) 1995-04-11
DK0497150T3 (da) 1998-06-02
EP0497150A1 (en) 1992-08-05
ZA92392B (en) 1992-10-28
AU1039792A (en) 1992-08-06
HU9200278D0 (en) 1992-04-28
JP2758766B2 (ja) 1998-05-28
KR920014805A (ko) 1992-08-25
EP0497150B1 (en) 1998-03-18
AU642573B2 (en) 1993-10-21
CZ281429B6 (cs) 1996-09-11
NO920298D0 (no) 1992-01-22
AU647992B2 (en) 1994-03-31
SK279004B6 (sk) 1998-05-06
IL100711A0 (en) 1992-09-06
CN1066847A (zh) 1992-12-09
ATE164158T1 (de) 1998-04-15
CN1037440C (zh) 1998-02-18
ES2117014T3 (es) 1998-08-01
IE920142A1 (en) 1992-07-29
FI920217A0 (fi) 1992-01-17
TW282467B (enExample) 1996-08-01
NZ241343A (en) 1994-06-27
CA2060154A1 (en) 1992-07-31
NO920298L (no) 1992-07-31
DE69224763T2 (de) 1998-07-09
HUT61748A (en) 1993-03-01
PL293316A1 (en) 1993-08-23
AU4490693A (en) 1993-11-18
US5290780A (en) 1994-03-01
GR3026592T3 (en) 1998-07-31
DE69224763D1 (de) 1998-04-23

Similar Documents

Publication Publication Date Title
EP0612244A4 (en) ENDOTHELINE RECEPTOR ANTAGONISTS.
FI920217L (fi) Angiotensin ii receptor blockerande 2,3,6-substituerade kinazolinoner.
FI903331A7 (fi) Angiotensiini-II-antagonisteina käyttökelpoisia substituoituja kinatsolinoneja
EP0475206A3 (en) Angiotensin ii receptor antagonists
FI933810L (fi) Reseptorantagonister av exiterbara aminosyror
DE69327720D1 (de) Endothelin rezeptor antagonisten
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi) Fibrinogeenireseptorin antagonisteja
NO944421D0 (no) Substituerte 1,2,3,4-tetrahydroisokinoliner med angiotensin II reseptoraktivitet
FI932518A7 (fi) Angiotensiinin II antagonistit
ID19623A (id) Antagonis reseptor vitronektin
FI932517A7 (fi) Angiotensiinin II antagonistit
DE69612698D1 (de) Pyrimidindion-, Pyrimidintrion-, Triazindion-Derivate als alpha-1-adrenergische Rezeptorantagonisten
FI922143A7 (fi) Muscarinreceptorantagonister.
MA23172A1 (fr) Antagonistes de recepteurs d'endotheline .
AU3276293A (en) Angiotensin II receptor antagonists
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
DE69204920D1 (de) Angiotensin-II-Antagoniste.
NO931364D0 (no) Tachykinin reseptorantagonister, isokinoloner og deres fremstilling
FI943359A7 (fi) Atsasykliset-heterosykliset yhdisteet angiotensiini II reseptoriantagonisteina
MX9207443A (es) Antagonistas receptores de angiotensina ii.
FI922346A7 (fi) Muscarinreceptorantagonister.
MX9203694A (es) Antagonistas de receptores de angiotensina ii.
FI941117A0 (fi) Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina
LV10425A (lv) Fibrinogena receptoru antagonisti